Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    TH3RESA
Show Display Options
Rank Status Study
1 Active, not recruiting
Has Results
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy
Condition: Breast Cancer
Interventions: Drug: Trastuzumab emtansine;   Drug: Treatment of physician's choice

Indicates status has not been verified in more than two years